Market Overview

UPDATE: D.A. Davidson Downgrades General Cable

Share:

In a note released Tuesday, D.A. Davidson downgraded General Cable (NYSE: BGC) from Buy to Neutral and lowered the price target from $34 to $28.

Davidson analyst Brent Theilman emphasized reduced guidance for the first quarter as well as "inconsistency in guidance over the past several quarters" as the main reasons for the downgrade. General Cable recently lowered it first quarter operating income guidance from $30-$45 million to $17-$27 million citing poor performance in Venezuela, challenging weather in North America, and reduced copper prices.

Theilman noted, the company now expects its full-year operating income to be at the low end of guidance ($260-$300 million). On this subject, Theilman wrote, "We are maintaining estimates for the remainder of the year, as General Cable should see a seasonal ramp in earnings; however, our full-year operating income forecast is now below the low end of guidance, given our reduced Q1 estimate."

At last check General Cable was trading down just over one percent for the day.

Latest Ratings for BGC

DateFirmActionFromTo
Dec 2016Initiates Coverage OnNeutral
May 2015MaintainsBuy
Apr 2015MaintainsNeutral

View More Analyst Ratings for BGC
View the Latest Analyst Ratings

Posted-In: Brent Theilman D.A. DavidsonAnalyst Color Upgrades Price Target Analyst Ratings

 

Related Articles (BGC)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
WEEDMKM PartnersMaintains30.0
NKTRH.C. WainwrightMaintains32.0
DISCARosenblattMaintains33.0
GOODNational SecuritiesInitiates Coverage On25.0
XOGCitiDowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

UPDATE: Darden Says Will Review Latest Materials, Has Engaged Goldman, Morgan Stanley as Advisors

Glaxosmithkline Confirms Warning Letter Received from FDA o March 19, 2014 Regarding Inspection Carried October 2013 Inspection; Company is Reviewing Contents of Letter -Reuters